Man Group PLC I Mab Transaction History

Man Group PLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.54 - $2.37 $37,503 - $57,716	24,353 Added 22.01%	134,977 $251,000
Q4 2023 Feb 14, 2024	BUY	$1.21 - $1.9 $133,855 - $210,185	110,624 New	110,624 $210,000
Q2 2021 Aug 16, 2021	SELL	$47.86 - $83.95 $397,094 - $696,533	-8,297 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$44.38 - $63.97 $368,220 - $530,759	8,297 New	8,297 $402,000

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $74.8M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

Stay updated on Man Group PLC with notifications on news.